> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Primary Endpoint Met in Alecensa Study: Roche
- URL: https://www.fdaweb.com/primary-endpoint-met-in-alecensa-study-roche/
- Published: 2023-09-01T12:00:00.000Z
- Updated: 2026-09-14T18:54:19.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155232

Roche says recent data from its Phase 3 ALINA study evaluating Alecensa (alectinib) compared with platinum-based chemotherapy met its primary endpoint of disease-free survival (DFS) in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). The data, which was unveiled during a prespecified interim analysis, also shows that Alecensa demonstrated a “statistically significant and clinically meaningful improvement in DFS as adjuvant therapy in people with completely resected stage 1B (tumor greater than 4cm) to 3A ALK)-positive NSCLC,” according to the company. It notes that overall survival data were “immature” when the analysis took place.

Alecensa is currently FDA-approved as an initial (first-line) treatment for ALK-positive, metastatic NSCLC. Roche says the latest results will be presented at an upcoming medical meeting and submitted to the agency to support expanded approval.